Onesource Specialty Pharma · NSE: ONESOURCE · BSE: 544292
Q1 FY26 results · Apr–Jun 2025
Onesource Specialty Pharma reported revenue from operations of ₹327.27 crore and net loss of ₹0.19 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 327.27 | — | — | 425.95 | −23.2% |
| Other income | 5.27 | — | — | 2.89 | +82.3% |
| Total income | 332.54 | — | — | 428.84 | −22.5% |
| Profit before tax | (4.40) | — | — | 83.50 | Turned loss |
| Net profit for the period | (0.19) | — | — | 98.20 | Turned loss |
| EPS, basic (₹) | (0.02) | — | — | 8.61 | Turned loss |
| Net margin (%) | -0.1 | — | 23.1 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 321.01 | — | — | 477.41 | −32.8% |
| Other income | 5.25 | — | — | 3.91 | +34.4% |
| Total income | 326.27 | — | — | 481.32 | −32.2% |
| Profit before tax | 24.82 | — | — | 174.88 | −85.8% |
| Net profit for the period | 24.82 | — | — | 174.19 | −85.8% |
| EPS, basic (₹) | 2.17 | — | — | 15.28 | −85.8% |
| Net margin (%) | 7.7 | — | 36.5 |
Consolidated
- Filed with BSE
- 04 Aug 2025, 20:53 IST
- Board meeting
- 04 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Aug 2025, 20:53 IST
- Board meeting
- 04 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE